Kingdon Capital Management, L.L.C. Editas Medicine, Inc. Transaction History
Kingdon Capital Management, L.L.C.
- $639 Million
- Q2 2025
A detailed history of Kingdon Capital Management, L.L.C. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Kingdon Capital Management, L.L.C. holds 100,000 shares of EDIT stock, worth $301,000. This represents 0.5% of its overall portfolio holdings.
Number of Shares
100,000Holding current value
$301,000% of portfolio
0.5%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding EDIT
# of Institutions
214Shares Held
45.4MCall Options Held
476KPut Options Held
338K-
Black Rock Inc. New York, NY7.78MShares$23.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.16MShares$21.6 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.96MShares$5.91 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.88MShares$5.65 Million0.0% of portfolio
-
State Street Corp Boston, MA1.85MShares$5.56 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $207M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...